- Home
- BRNS
as 11-15-2024 4:00pm EST
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
| Founded: | 2016 | Country: | United Kingdom |
| Employees: | N/A | City: | DIDCOT |
| Market Cap: | 52.0M | IPO Year: | 2021 |
| Target Price: | $4.00 | AVG Volume (30 days): | 31.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $4.16 | Next Earning Date: | 11-06-2024 |
| Revenue: | $14,969,000 | Revenue Growth: | 106.21% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Barinthus Biotherapeutics plc News
BRNS Breaking Stock News: Dive into BRNS Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
GlobeNewswire
2 days ago
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewswire
11 days ago
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
GlobeNewswire
17 days ago
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Simply Wall St.
25 days ago
ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch
GlobeNewswire
2 months ago
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
GlobeNewswire
2 months ago
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
GlobeNewswire
3 months ago
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Compare BRNS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRNS Barinthus Biotherapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.